학술논문
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
Document Type
article
Author
Doris Leithner; Jessica R. Flynn; Sean M. Devlin; Audrey Mauguen; Teng Fei; Shang Zeng; Junting Zheng; Brandon S. Imber; Harper Hubbeling; Marius E. Mayerhoefer; Akshay Bedmutha; Efrat Luttwak; Magdalena Corona; Parastoo B. Dahi; Alejandro Luna de Abia; Ivan Landego; Richard J. Lin; M. Lia Palomba; Michael Scordo; Jae H. Park; Ana Alarcon Tomas; Gilles Salles; Daniel Lafontaine; Laure Michaud; Gunjan L. Shah; Miguel-Angel Perales; Roni Shouval; Heiko Schöder
Source
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Subject
Language
English
ISSN
1756-8722
Abstract
Abstract Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined radiomic features extracted from pre-CAR-T 18F-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) scans (n = 341) of 180 patients (121 male; median age, 66 years). Three conventional (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and 116 novel radiomic features were assessed, along with inflammatory markers, toxicities, and outcomes. At both pre-apheresis and pre-infusion time points, conventional PET features of disease correlated with elevated inflammatory markers. At pre-infusion, MTV was associated with grade ≥ 2 cytokine release syndrome (odds ratio [OR] for 100 mL increase: 1.08 [95% confidence interval (CI), 1.01–1.20], P = 0.031), and SUVmax was associated with failure to achieve complete response (CR) (OR 1.72 [95% CI, 1.24–2.43], P